Though considerable advances have been made in the prevention and treatment of HIV/AIDS, more than 1.2 million people in the U.S. are still affected by the disease. CytoDyn Inc.’s (OTCQB: CYDY) PRO 140 candidate is considered one of the most advanced experimental monoclonal antibodies for HIV treatment, and it has been used in more than 140 HIV-positive patients in placebo-controlled and open label FDA-approved clinical trials. “The drug has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test patients and has been designated a ‘fast track’ product candidate by the FDA. If approved for commercialization, PRO 140 could face a $20 billion U.S. HIV therapeutics market that is plagued with a number of ills, including difficult dosing schedules, resistance to currently used drugs, and, worst of all, the debilitating toxicity of standard highly active antiretroviral therapy (HAART). PRO 140 has been shown to address the weaknesses of HAART with no serious side effects, hardly any toxicity and no drug resistance when self-administered as a dose-a-week subcutaneous injection.”
To view the full article, visit: http://nnw.fm/vn4Hv
About CytoDyn
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed phase 2 clinical trials with demonstrated antiviral activity in man and is currently in phase 3. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven phase 1 and phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy. CytoDyn intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV and to pursue non-HIV indications where CCR5 and its ligand CCL5 may be involved. For more information on the company, please visit www.cytodyn.com.
About NetworkNewsBreak
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
